Endo Health Solutions to Buy Boca Pharmacal for $225M
Endo Health Solutions (NASDAQ: ENDP) today announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash. The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.